Trials / Recruiting
RecruitingNCT07290205
Remimazolam NeuroImaging
Neuroimaging of Sedation With Remimazolam
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Keith M Vogt · Academic / Other
- Sex
- All
- Age
- 18 Years – 59 Years
- Healthy volunteers
- Accepted
Summary
This is a single-arm functional MRI study that will determine the effects of remimazolam on cognition and brain activity and connectivity at rest, during noxious stimulation, and during a memory encoding task
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Remimazolam | Subjects in this group will receive an intravenous infusion of this drug, during a portion of the study. |
| DEVICE | Peripheral Nerve Stimulation | Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired with a fixed number of the experimental cues, in a pattern that appears random to participants. |
Timeline
- Start date
- 2026-03-27
- Primary completion
- 2027-12-01
- Completion
- 2027-12-02
- First posted
- 2025-12-18
- Last updated
- 2026-04-02
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07290205. Inclusion in this directory is not an endorsement.